Linked Life Data

15190684

Source:http://linkedlifedata.com/resource/pubmed/id/15190684

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-6-11
pubmed:abstractText
Cholinergic abnormalities, alongside senile plaques, neurofibrillary tangles, and extensive neuronal loss, are the major characteristics in Alzheimer's disease (AD). Both nicotinic and muscarinic acetylcholine receptors are decreased in AD, and it has been shown that the reduction in the number of acetylcholine receptors precedes other pathologic changes. Anti-cholinergic drugs induce amnesia, which can be reversed by withdrawal of the medication. Inhibition of the down-regulation of acetylcholine is, therefore, a strategy for the treatment of AD because it could augment acetylcholine levels within synaptic clefts. In this context, acetylcholinesterase inhibitors, which improve cognitive functions, are currently approved for the treatment of AD. Stimulation of acetylcholine receptors, nicotinic or muscarinic, is another strategy; some drugs are currently under investigation, and reported to be effective. In addition, nicotinic stimulation exerts a neuroprotective effect, and reduces the amyloid burden. Cholinergic therapy may counter the symptoms and progress of AD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0065-1400
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
99-105
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Alzheimer's disease and acetylcholine receptors.
pubmed:affiliation
Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyoku, Kyoto 606-8507, Japan.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't